Clinical Trials by Novartis Grouped by Interventions Over Time

Novartis's clinical trials: A timeline of innovation and impact.

__timestampNovartis, DRUG: TegaserodNovartis Pharmaceuticals, DRUG: DeferasiroxNovartis Pharmaceuticals, DRUG: EverolimusNovartis Pharmaceuticals, DRUG: Nilotinib
Monday, July 1, 20021
Thursday, May 1, 20031
Sunday, June 1, 20031
Monday, September 1, 20031
Saturday, November 1, 20031
Thursday, January 1, 20043
Monday, March 1, 200411
Thursday, April 1, 20042
Saturday, May 1, 20042
Sunday, August 1, 20041
Wednesday, September 1, 20042
Friday, October 1, 20041
Wednesday, December 1, 20041
Tuesday, February 1, 200511
Friday, April 1, 2005211
Sunday, May 1, 20051
Wednesday, June 1, 20051
Friday, July 1, 20051
Monday, August 1, 20051
Thursday, September 1, 20051
Saturday, October 1, 20051
Thursday, June 1, 20061
Saturday, July 1, 20062
Sunday, October 1, 20061
Wednesday, November 1, 200611
Friday, December 1, 20061
Monday, January 1, 20071
Thursday, February 1, 20071
Sunday, April 1, 20071
Tuesday, May 1, 20071
Wednesday, August 1, 20071
Saturday, September 1, 20071
Friday, February 1, 20081
Saturday, March 1, 20081
Friday, August 1, 200822
Monday, September 1, 20082
Wednesday, October 1, 20081
Saturday, November 1, 20081
Thursday, January 1, 20091
Sunday, February 1, 20091
Monday, June 1, 20091
Sunday, November 1, 20091
Tuesday, December 1, 200912
Friday, January 1, 20101
Saturday, May 1, 20101
Monday, November 1, 20101
Saturday, January 1, 20111
Friday, April 1, 20112
Thursday, December 1, 20111
Thursday, March 1, 20121
Friday, March 1, 20131
Monday, April 1, 20131
Saturday, June 1, 20131
Wednesday, January 1, 20141
Saturday, February 1, 20141
Tuesday, July 1, 20141
Tuesday, December 1, 20151
Monday, February 1, 20161
Monday, August 1, 20161
Monday, January 1, 20181
Thursday, November 1, 20181
Monday, May 1, 20231
Loading chart...

Unleashing the power of data

Novartis Clinical Trials: A Journey Through Time

Exploring the Impact of Key Interventions

Since the early 2000s, Novartis has been at the forefront of pharmaceutical innovation, conducting numerous clinical trials to bring groundbreaking treatments to market. This chart highlights the evolution of Novartis's clinical trials, focusing on key interventions such as Tegaserod, Deferasirox, Everolimus, and Nilotinib.

In July 2002, Deferasirox trials began, marking a significant step in treating iron overload. By 2003, Tegaserod trials emerged, peaking in early 2004 with a 200% increase in activity. Meanwhile, Everolimus trials started in late 2003, contributing to advancements in cancer treatment. Nilotinib trials, commencing in the mid-2000s, have consistently supported leukemia research.

While some data points are missing, the overall trend showcases Novartis's commitment to medical progress. This timeline not only reflects the company's strategic focus but also underscores its role in shaping modern medicine.

Published by
National Center for Biotechnology Information

Source link
clinicaltrials.gov

Date published
29 Nov 2024